Down syndrome and the complexity of genome dosage imbalance

Nature Reviews Genetics

Volumn 18, Issue 3, 2017, Pages 147-163

  Antonarakis, Stylianos E ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; SONIC HEDGEHOG PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; AGING; ALZHEIMER DISEASE; BRAIN DEPTH STIMULATION; CHILDHOOD LEUKEMIA; CHOLINERGIC SYSTEM; CHROMOSOME 21; CONGENITAL HEART MALFORMATION; DENDRITIC SPINE; DOWN SYNDROME; GABAERGIC SYSTEM; GENE DOSAGE; GENE EXPRESSION; GENE SILENCING; HAPLOINSUFFICIENCY; HUMAN; INTELLECTUAL IMPAIRMENT; INTRACELLULAR SIGNALING; LEUKEMIA; MOLECULAR GENETICS; MOUSE MODEL; MYELOPROLIFERATIVE DISORDER; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; TRISOMY 21; ANIMAL; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; GENOME; MOUSE;

ANIMALS; DOWN SYNDROME; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENOME; HUMANS; MICE; PHENOTYPE;

EID: 85007480630     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg.2016.154     Document Type: Review

References (159)

1. Langdon-Down, J. Observations on an ethnic classification of idiots. London Hospital Reports 3, 259-262 (1866).
2. LeJeune, J., Gautier, M. & Turpin, R. Etudes des chromosomes somatiques de neufs enfants mongoliens. C. R. Hebd Seances Acad. Sci. 248, 1721-1722 (in French) (1959).
3. Davisson, M. T., Schmidt, C. & Akeson, E. C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. 360, 263-280 (1990).
4. Hattori, M. et al. The DNA sequence of human chromosome 21. Nature 405, 311-319 (2000).
5. Antonarakis, S. E. 10 years of genomics, chromosome 21, and Down syndrome. Genomics 51, 1-16 (1998).
6. Antonarakis, S. E. Chromosome 21: from sequence to applications. Curr. Opin. Genet. Dev. 11, 241-246 (2001).
7. Antonarakis, S. E. & Epstein, C. J. The challenge of Down syndrome. Trends Mol. Med. 12, 473-479 (2006).
8. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A. & Deutsch, S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 5, 725-738 (2004).
9. Letourneau, A. & Antonarakis, S. E. Genomic determinants in the phenotypic variability of Down syndrome. Prog. Brain Res. 197, 15-28 (2012).
10. Hartley, D. et al. Down syndrome and Alzheimer's disease: common pathways, common goals. Alzheimers Dement. 11, 700-709 (2015).
11. Wiseman, F. K. et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 16, 564-574 (2015).
12. Dierssen, M. Down syndrome: the brain in trisomic mode. Nat. Rev. Neurosci. 13, 844-858 (2012).
13. Reeves, R. H., Baxter, L. L. & Richtsmeier, J. T. To o much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet. 17, 83-88 (2001).
14. Reeves, R. H. & Garner, C. C. A year of unprecedented progress in Down syndrome basic research. Ment. Retard. Dev. Disabil. Res. Rev. 13, 215-220 (2007).
15. Salehi, A., Faizi, M., Belichenko, P. V. & Mobley, W. C. Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 13, 207-214 (2007).
16. Lo, Y. M. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485-487 (1997).
17. Chiu, R. W. et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc. Natl Acad. Sci. USA 105, 20458-20463 (2008).
18. Wong, F. C. & Lo, Y. M. Prenatal diagnosis innovation: genome sequencing of maternal plasma. Annu. Rev. Med. 67, 419-432 (2016).
19. Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
20. Emmrich, S. et al. miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes Dev. 28, 858-874 (2014).
21. O'Loghlen, A. et al. MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation. Cell Stem Cell 10, 33-46 (2012).
22. Bamburg, J. R. & Bloom, G. S. Cytoskeletal pathologies of Alzheimer disease. Cell Motil. Cytoskeleton 66, 635-649 (2009).
23. Letourneau, A. et al. HSA21 single-minded 2 (Sim2) binding sites co-localize with super-enhancers and pioneer transcription factors in pluripotent mouse ES cells. PLoS ONE 10, e0126475 (2015).
24. Costa, V. et al. Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21. PLoS ONE 6, e18493 (2011).
25. Sethupathy, P. et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR13' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am. J. Hum. Genet. 81, 405-413 (2007).
26. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501, 506-511 (2013).
27. Gutierrez-Arcelus, M. et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. eLife 2, e00523 (2013).
28. Gutierrez-Arcelus, M. et al. Correction: passive and active DNA methylation and the interplay with genetic variation in gene regulation. eLife 2, e01045 (2013).
29. Kilpinen, H. et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science 342, 744-747 (2013).
30. Waszak, S. M. et al. Population variation and genetic control of modular chromatin architecture in humans. Cell 162, 1039-1050 (2015).
31. Olmos-Serrano, J. L. et al. Down syndrome developmental brain transcriptome reveals defective oligodendrocyte differentiation and myelination. Neuron 89, 1208-1222 (2016).
32. Prandini, P. et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am. J. Hum. Genet. 81, 252-263 (2007).
33. Dahoun, S. et al. Monozygotic twins discordant for trisomy 21 and maternal 21q inheritance: a complex series of events. Am. J. Med. Genet. A 146A, 2086-2093 (2008).
34. Letourneau, A. et al. Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature 508, 345-350 (2014).
35. Guelen, L. et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature 453, 948-951 (2008).
36. Pope, B. D. & Gilbert, D. M. Genetics: up and down in Down's syndrome. Nature 508, 323-324 (2014).
37. Hibaoui, Y. & Feki, A. Human pluripotent stem cells: applications and challenges in neurological diseases. Front. Physiol. 3, 267 (2012).
38. Briggs, J. A. et al. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells 31, 467-478 (2013).
39. Sullivan, K. D. et al. Trisomy 21 consistently activates the interferon response. eLife 5, e16220 (2016).
40. Tan, Y. H., Schneider, E. L., Tischfield, J., Epstein, C. J. & Ruddle, F. H. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science 186, 61-63 (1974).
41. Wisniewski, K. E., Wisniewski, H. M. & Wen, G. Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278-282 (1985).
42. Wu, J. & Morris, J. K. The population prevalence of Down's syndrome in England and Wales in 2011. Eur. J. Hum. Genet. 21, 1016-1019 (2013).
43. Rumble, B. et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 320, 1446-1452 (1989).
44. Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32 (1996).
45. Hooli, B. V. et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78, 1250-1257 (2012).
46. Theuns, J. et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am. J. Hum. Genet. 78, 936-946 (2006).
47. Prasher, V. P. et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43, 380-383 (1998).
48. GTEx Consortium. Human genomics. the Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660 (2015).
49. Teller, J. K. et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2, 93-95 (1996).
50. Salehi, A. et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42 (2006).
51. Granholm, A. C., Sanders, L. A. & Crnic, L. S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 161, 647-663 (2000).
52. Whitehouse, P. J. et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237-1239 (1982).
53. Yates, C. M., Simpson, J., Maloney, A. F., Gordon, A. & Reid, A. H. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet 2, 979 (1980).
54. Cataldo, A. M. et al. Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277-286 (2000).
55. Xu, W. et al. Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J. Clin. Invest. 126, 1815-1833 (2016).
56. Cossec, J. C. et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum. Mol. Genet. 21, 3156-3172 (2012).
57. Zhu, L. et al. Reduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model. J. Biol. Chem. 288, 32050-32063 (2013).
58. Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355, 165-169 (2000).
59. Zipursky, A., Poon, A. & Doyle, J. Leukemia in Down syndrome: a review. Pediatr. Hematol. Oncol. 9, 139-149 (1992).
60. Al-Kasim, F. et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol. 24, 9-13 (2002).
61. Hitzler, J. K. & Zipursky, A. Origins of leukaemia in children with Down syndrome. Nat. Rev. Cancer 5, 11-20 (2005).
62. Mateos, M. K., Barbaric, D., Byatt, S. A., Sutton, R. & Marshall, G. M. Down syndrome and leukemia: insights into leukemogenesis and translational targets. Transl Pediatr. 4, 76-92 (2015).
63. Buitenkamp, T. D. et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123, 70-77 (2014).
64. Mullighan, C. G. et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243-1246 (2009).
65. Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115, 1006-1017 (2010).
66. Nikolaev, S. I. et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat. Commun. 5, 4654 (2014).
67. Lane, A. A. et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat. Genet. 46, 618-623 (2014).
68. Roy, A., Roberts, I., Norton, A. & Vyas, P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br. J. Haematol. 147, 3-12 (2009).
69. Roberts, I. et al. G ATA 1 -mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 122, 3908-3917 (2013).
70. Yoshida, K. et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat. Genet. 45, 1293-1299 (2013).
71. Elagib, K. E. et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101, 4333-4341 (2003).
72. Stankiewicz, M. J. & Crispino, J. D. AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia 27, 1339-1347 (2013).
73. Harewood, L. et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 17, 547-553 (2003).
74. Weber, S. et al. Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia. Genes Chromosomes Cancer 55, 148-157 (2016).
75. Banno, K. et al. Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities. Cell Rep. 15, 1228-1241 (2016).
76. Malinge, S., Izraeli, S. & Crispino, J. D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113, 2619-2628 (2009).
77. Nikolaev, S. I. et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood 122, 554-561 (2013).
78. Malinge, S. et al. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood 122, e33-e43 (2013).
79. Ferencz, C. et al. Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J. Pediatr. 114, 79-86 (1989).
80. Roizen, N. J. & Patterson, D. Down's syndrome. Lancet 361, 1281-1289 (2003).
81. Barlow, G. M. et al. Down syndrome congenital heart disease: a narrowed region and a candidate gene. Genet. Med. 3, 91-101 (2001).
82. Korbel, J. O. et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl Acad. Sci. USA 106, 12031-12036 (2009).
83. Lyle, R. et al. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur. J. Hum. Genet. 17, 454-466 (2009).
84. Dunlevy, L. et al. Down's syndrome-like cardiac developmental defects in embryos of the transchromosomic Tc 1 mouse. Cardiovasc. Res. 88, 287-295 (2010).
85. Yu, T. et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum. Mol. Genet. 19, 2780-2791 (2010).
86. Sago, H. et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl Acad. Sci. USA 95, 6256-6261 (1998).
87. Shinohara, T. et al. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down's syndrome. Hum. Mol. Genet. 10, 1163-1175 (2001).
88. Lana-Elola, E. et al. Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel. eLife 5, e11614 (2016).
89. Grossman, T. R. et al. Over-expression of DSCAM and COL6A2 cooperatively generates congenital heart defects. PLoS Genet. 7, e1002344 (2011).
90. Sailani, M. R. et al. The complex SNP and CNV genetic architecture of the increased risk of congenital heart defects in Down syndrome. Genome Res. 23, 1410-1421 (2013).
91. Ramachandran, D. et al. Genome-wide association study of Down syndrome-associated atrioventricular septal defects. G35, 1961-1971 (2015).
92. van Bon, B. W. et al. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. Clin. Genet. 79, 296-299 (2011).
93. Ji, J. et al. DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies. Eur. J. Hum. Genet. 23, 1473-1481 (2015).
94. Conrad, B. & Antonarakis, S. E. Gene duplication: a drive for phenotypic diversity and cause of human disease. Annu. Rev. Genomics Hum. Genet. 8, 17-35 (2007).
95. Becker, W., Soppa, U. & Tejedor, F. J. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. CNS Neurol. Disord. Drug Targets 13, 26-33 (2014).
96. Huang, N., Lee, I., Marcotte, E. M. & Hurles, M. E. Characterising and predicting haploinsufficiency in the human genome. PLoS Genet. 6, e1001154 (2010).
97. Steinberg, J., Honti, F., Meader, S. & Webber, C. Haploinsufficiency predictions without study bias. Nucleic Acids Res. 43, e101 (2015).
98. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285-291 (2016).
99. Olson, L. E., Richtsmeier, J. T., Leszl, J. & Reeves, R. H. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306, 687-690 (2004).
100. Pereira, P. L. et al. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum. Mol. Genet. 18, 4756-4769 (2009).
101. Brault, V. et al. Opposite phenotypes of muscle strength and locomotor function in mouse models of partial trisomy and monosomy 21 for the proximal Hspa13-App region. PLoS Genet. 11, e1005062 (2015).
102. Li, Z. et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum. Mol. Genet. 16, 1359-1366 (2007).
103. Liu, C. et al. Genetic analysis of Down syndrome-associated heart defects in mice. Hum. Genet. 130, 623-632 (2011).
104. Liu, C. et al. Engineered chromosome-based genetic mapping establishes a 3.7 Mb critical genomic region for Down syndrome-associated heart defects in mice. Hum. Genet. 133, 743-753 (2014).
105. Hernandez, D., Mee, P. J., Martin, J. E., Tybulewicz, V. L. & Fisher, E. M. Transchromosomal mouse embryonic stem cell lines and chimeric mice that contain freely segregating segments of human chromosome 21. Hum. Mol. Genet. 8, 923-933 (1999).
106. Duchon, A., Besson, V., Pereira, P. L., Magnol, L. & Herault, Y. Inducing segmental aneuploid mosaicism in the mouse through targeted asymmetric sister chromatid event of recombination. Genetics 180, 51-59 (2008).
107. De la Torre, R. et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol. Nutr. Food Res. 58, 278-288 (2014).
108. Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411-413 (2007).
109. Park, I. H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877-886 (2008).
110. Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl Med. 4, 124ra29 (2012).
111. Mou, X. et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res. Ther. 3, 14 (2012).
112. Lu, H. E. et al. Modeling neurogenesis impairment in Down syndrome with induced pluripotent stem cells from trisomy 21 amniotic fluid cells. Exp. Cell Res. 319, 498-505 (2013).
113. Maclean, G. A. et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc. Natl Acad. Sci. USA 109, 17567-17572 (2012).
114. Chou, S. T. et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc. Natl Acad. Sci. USA 109, 17573-17578 (2012).
115. Li, L. B. et al. Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11, 615-619 (2012).
116. Weick, J. P. et al. Deficits in human trisomy 21 iPSCs and neurons. Proc. Natl Acad. Sci. USA 110, 9962-9967 (2013).
117. Jiang, J. et al. Translating dosage compensation to trisomy 21. Nature 500, 296-300 (2013).
118. Chen, C. et al. Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat. Commun. 5, 4430 (2014).
119. Murray, A. et al. Isogenic induced pluripotent stem cell lines from an adult with mosaic Down syndrome model accelerated neuronal ageing and neurodegeneration. Stem Cells 33, 2077-2084 (2015).
120. Zhao, C., Deng, W. & Gage, F. H. Mechanisms and functional implications of adult neurogenesis. Cell 132, 645-660 (2008).
121. Stagni, F., Giacomini, A., Guidi, S., Ciani, E. & Bartesaghi, R. Timing of therapies for Down syndrome: the sooner, the better. Front. Behav. Neurosci. 9, 265 (2015).
122. Braudeau, J. et al. Chronic treatment with a promnesiant GABA-A α5-selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down syndrome mouse model. Adv. Pharmacol. Sci. 2011, 153218 (2011).
123. A α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J. Neurosci. 33, 3953-3966 (2013).
124. Guedj, F. et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 4, e4606 (2009).
125. Stagni, F. et al. Treatment with epigallocatechin gallate rescues neurogenesis and neuron maturation in the Ts65Dn mouse model of Down syndrome. (Symposia abstract). Neuropsychol. Trends 16, 120 (2014).
126. Hibaoui, Y. et al. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol. Med. 6, 259-277 (2014).
127. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01394796 (2010).
128. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01699711 (2012).
129. de la Torre, R. et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 801-810 (2016).
130. Roper, R. J. et al. Defective cerebellar response to mitogenic Hedgehog signaling in Down's syndrome mice. Proc. Natl Acad. Sci. USA 103, 1452-1456 (2006).
131. Das, I. et al. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci. Transl Med. 5, 201ra120 (2013).
132. Belichenko, P. V. et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 480, 281-298 (2004).
133. Clark, S., Schwalbe, J., Stasko, M. R., Yarowsky, P. J. & Costa, A. C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 200, 256-261 (2006).
134. Bianchi, P. et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 30, 8769-8779 (2010).
135. Guidi, S. et al. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Brain Pathol. 23, 129-143 (2013).
136. Stagni, F. et al. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome. PLoS ONE 8, e61689 (2013).
137. Stagni, F. et al. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Neurobiol. Dis. 74, 204-218 (2015).
138. Moon, J. et al. Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav. Neurosci. 124, 346-361 (2010).
139. Velazquez, R. et al. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 58, 92-101 (2013).
140. Ash, J. A. et al. Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiol. Dis. 70, 32-42 (2014).
141. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02500784 (2015).
142. Brown, C. J. et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell 71, 527-542 (1992).
143. Chakrabarti, L., Galdzicki, Z. & Haydar, T. F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 27, 11483-11495 (2007).
144. Lott, I. T. Neurological phenotypes for Down syndrome across the life span. Prog. Brain Res. 197, 101-121 (2012).
145. Hyde, L. A., Frisone, D. F. & Crnic, L. S. Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav. Brain Res. 118, 53-60 (2001).
146. Kleschevnikov, A. M. et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153-8160 (2004).
147. Galdzicki, Z. & Siarey, R. J. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav. 2, 167-178 (2003).
148. Hamani, C. et al. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann. Neurol. 63, 119-123 (2008).
149. Shirvalkar, P. R., Rapp, P. R. & Shapiro, M. L. Bidirectional changes to hippocampal theta-gamma comodulation predict memory for recent spatial episodes. Proc. Natl Acad. Sci. USA 107, 7054-7059 (2010).
150. Hao, S. et al. Forniceal deep brain stimulation rescues hippocampal memory in Rett syndrome mice. Nature 526, 430-434 (2015).
151. Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188 (1999).
152. Belichenko, P. V. et al. An anti-β-amyloid vaccine for treating cognitive deficits in a mouse model of Down syndrome. PLoS ONE 11, e0152471 (2016).
153. Lancaster, M. A. et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373-379 (2013).
154. Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19, 149-150 (2003).
155. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. Science 322, 881-888 (2008).
156. Harrow, J. et al. GENCODE: the reference human genome annotation for the ENCODE Project. Genome Res. 22, 1760-1774 (2012).
157. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49 (2011).
158. Neph, S. et al. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature 489, 83-90 (2012).
159. Jurka, J. et al. Repbase Update, a database of eukaryotic repetitive elements. Cytogenet. Genome Res. 110, 462-467 (2005).